Latest Commercial Processing News

Resolution Minerals reports outstanding high-grade antimony, silver, and gold assay results from rock samples at its Antimony Ridge Mine in Idaho, reinforcing the project's strategic importance in the US critical minerals landscape.

Neurizon Therapeutics has completed manufacturing three GMP registration batches of its lead ALS drug candidate NUZ-001 ahead of schedule, paving the way for FDA submissions and clinical trial enrollment.

BPM Minerals reports outstanding high-grade rare earth element assays from its Durack Project in Western Australia, highlighting the potential for a major monazite-hosted REE deposit. The discovery aligns with growing global demand and Australian government support for critical minerals.

ABx Group has achieved over 98% retention of rare earth elements with near-complete impurity removal in large batch tests from its Deep Leads project, advancing toward delivering its first mixed rare earth carbonate sample by November’s end.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.

Lunnon Metals has completed a detailed Scoping Study for its Lady Herial gold project, highlighting a high-grade open pit opportunity underpinned by predominantly measured resources. The company is advancing commercial negotiations and regulatory approvals, setting the stage for potential near-term development.

Lunnon Metals has completed a detailed Scoping Study for its Lady Herial gold deposit, confirming a short-life, high-grade open pit opportunity with strong financial prospects. The study, based largely on Measured and Indicated Resources, sets the stage for commercial negotiations with Gold Fields and potential near-term production.

Taiton Resources reports exceptional high-purity quartz assay results from its Kingsgate Project in New South Wales, with SiO2 content reaching 99.97%, underpinning plans for further metallurgical testing and exploration.

Rhythm Biosciences has fast-tracked the integration of the geneType™ business, restoring full commercial capabilities ahead of schedule and setting the stage for expanded market reach.